Teva Offloads Women's Health Business To Two Firms For $1.38Bn
The generic drug maker signed two deals to divest its women's health business, one with the equity investment firm CVC Capital Partners and the other with Foundation Consumer Healthcare.
You may also be interested in...
After seven months of uncertainty, Teva has announced a new CEO. But Kåre Schultz, who has won applause for turning around the fortunes of Danish firm Lundbeck over the past two years, faces a daunting turnaround challenge when it comes to the generics behemoth.
The company is pursuing the sale of global women's health and its oncology and pain businesses in Europe, Interim CEO Yitzhak Peterburg said during the firm's first quarter earnings call.
Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.